Repare Therapeutics (RPTX) shares set for removal from Nasdaq listing

Rhea-AI Filing Summary

Repare Therapeutics Inc. is having its common shares removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certifies it has met the requirements to file Form 25 for this delisting action.

Positive

• None.

Negative

• Removal of Nasdaq listing and registration: Repare Therapeutics’ common shares are being struck from listing and registration on Nasdaq under Section 12(b), which typically reduces liquidity and may restrict access for certain investors.

Insights

Equity markets and listing standards analyst

Repare Therapeutics is being delisted from Nasdaq, a clearly adverse development for public shareholders.

The notification states that Repare Therapeutics’ common shares are being removed from listing and registration on Nasdaq under Section 12(b) of the Exchange Act via Form 25. This means the company’s stock will no longer trade on Nasdaq’s main market once the process is completed.

Loss of a major exchange listing typically reduces trading liquidity and may limit access for some institutional investors who require exchange-listed securities. Future disclosures in company filings may provide additional context on where the shares will trade and any follow-on regulatory or reporting implications.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39335

Issuer:	Repare Therapeutics Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	7171 FREDERICK BANTING
	SUITE 270, BUILDING 2
	SAINT-LAURENT	QUEBEC, CANADA	H4S 1Z9
Telephone number:					(857) 412-7018

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Shares

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-01-28	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Repare Therapeutics (RPTX) Form 25 filing mean?

The Form 25 filing means Repare Therapeutics’ common shares are being removed from listing and registration on Nasdaq. Nasdaq certifies it has met all requirements for this delisting action under Section 12(b) of the Securities Exchange Act of 1934.

Which securities of Repare Therapeutics (RPTX) are being delisted?

The filing specifies that Repare Therapeutics’ common shares are being removed from listing and registration on the Nasdaq Stock Market LLC. This affects the primary equity class that investors typically trade under the company’s Nasdaq listing.

Who initiated the removal of Repare Therapeutics (RPTX) from Nasdaq?

The document is a Form 25 filed by Nasdaq Stock Market LLC, which certifies it has reasonable grounds to believe it meets all requirements to strike Repare Therapeutics’ common shares from listing and registration under Section 12(b) of the Exchange Act.

What regulatory basis is cited for removing Repare Therapeutics (RPTX) from Nasdaq?

The notification references Section 12(b) of the Securities Exchange Act of 1934 and related SEC rules, including 17 CFR 240.12d2-2. Nasdaq states it has complied with its rules to strike the class of securities from listing and/or withdraw registration.

Who signed the Nasdaq delisting notice for Repare Therapeutics (RPTX)?

The notification is signed on behalf of Nasdaq Stock Market LLC by Jennifer Fainer, identified as a CDO Analyst. The signature certifies Nasdaq has reasonable grounds to believe it meets all requirements to file Form 25 for the delisting.

Does the Repare Therapeutics (RPTX) filing mention voluntary withdrawal by the issuer?

The document includes standard references to both exchange-initiated and issuer-related withdrawal provisions under Rule 12d2-2. However, in this excerpt, Nasdaq is the party certifying compliance and filing Form 25 to remove the common shares from listing.